MVM Medizinische Verwaltungs und Managementgesellschaft mbH
- Address
- lock Available on a paid plan
Digestive System Diseases
The Studienzentrum UnterEms at MVM Medizinische Verwaltungs und Managementgesellschaft mbH is conducting a series of studies focused on colorectal cancer and rectal cancer. These trials aim to improve outcomes such as disease‑free survival, organ preservation, and the effectiveness of adjuvant or peri‑operative therapies for patients across stages II to metastatic disease.
- Evaluating adjuvant chemotherapy guided by ctDNA status after resection of stage II colon cancer
- Comparing active post‑resection chemotherapy with structured follow‑up in metastatic colorectal disease
- Testing organ preservation approaches in intermediate‑ and high‑risk rectal cancer using short‑course radiotherapy or chemoradiotherapy
- Investigating peri‑operative immunotherapy for MSI‑high or MMR‑deficient colorectal tumors unsuitable for oxaliplatin
Together, these investigations reflect the site’s commitment to advancing therapeutic strategies for digestive system malignancies and to offering patients access to innovative treatment options.
Neoplasms
Research at the center also encompasses HR+/HER2‑negative early breast cancer, targeting improved invasive disease‑free survival through personalized adjuvant regimens that combine endocrine therapy with a CDK4/6 inhibitor.
- Comparing CDK4/6 inhibitor plus endocrine therapy versus standard endocrine therapy in intermediate to high‑risk early breast cancer
- Utilizing dynamic molecular markers to adjust adjuvant treatment intensity
- Assessing long‑term survival benefits of combined targeted and hormonal therapy
These neoplasm‑focused trials underline the site’s dedication to delivering cutting‑edge cancer care and expanding therapeutic options for patients with breast malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MVM Medizinische Verwaltungs und Managementgesellschaft mbH
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Amgen Inc. | Phase I | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 4 | Unknown | 2019-12-04 | 2021-11-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.